

Prevalence And Predictors of Hyperuricemia Among Adults with Chronic Diseases in Ethiopia: A Systematic Review and Meta-Analysis 2025

Amanuel Aklilu Alemu^{1*}, Sumeya Hussen Idris^{2*}, Elias Getahun Bayu⁵, Tsion Kebede Tegene³, Gebremedhin Hailay Tsadik^{1*}, Elias Gashaw Endegnanew¹, Biruk Tadesse Officer⁴, Haymanot Bekele Urga⁵, Misrak Handamo⁵, Tsion Tesfaye Degefu^{5*}, Sherefedin Kedir Rashed⁶, Temesgen Teklu Alemayehu⁴, Meron Teklay Girmay⁴ and Tewodros Kassahun Tarekegn¹

¹Department of Medicine, Addis Ababa University, College of Medicine and Health Science, Addis Ababa, Ethiopia

²Department of Medicine, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia

³Department of Medicine, Wolkite University, College of Medicine and Health Science, Ethiopia

⁴Department of Medicine, Hawassa University, College of Medicine and Health Science, Ethiopia

⁵Department of Medicine, University of Gondar, College of Medicine and Health Science

⁶Midwestern University, Glendale, Arizona, Master of Medical Science in Physician Assistant Studies (M.M.S.)

*Corresponding author

Sumeya Hussen Idris, Department of Medicine, College of Public Health and Medical Sciences, Jimma University, Jimma, Ethiopia. Gebremedhin Hailay Tsadik, Department of Medicine, Addis Ababa University, College of Medicine and Health Science, Addis Ababa, Ethiopia

Tsion Tesfaye Degefu, Department of Medicine, University of Gondar, College of Medicine and Health Science, Ethiopia

Received: February 07, 2026; **Accepted:** February 13, 2026; **Published:** February 20, 2026

ABSTRACT

Introduction: Hyperuricemia has been linked to gout, cardiovascular diseases, resistant hypertension, insulin resistance, chronic kidney disease, and progression of type 2 diabetes mellitus. Current population wide estimates of hyperuricemia are limited; data from related conditions such as gout and other chronic disease indicate a rising trend in both prevalence and disability. So, this study is aimed to estimate pooled prevalence and predictors of hyperuricemia among adult with chronic disease in Ethiopia

Methods: PubMed, Scopus, PsycINFO, and goggle scholar databases were used for this analysis. We assessed methodological quality using the Newcastle-Ottawa Scale. An inverse variance-weighted random-effects model meta-analysis was performed to estimate the pooled prevalence and odds ratio (OR) of determinants with a 95% confidence interval (CI). The I2 test statistic was used to check between-study heterogeneity, and the Egger's regression statistical test was used to check publication bias. A p-value of less than 0.05 used to declare statistical significance.

Results: All ten articles had good methodological quality and included 2917 participants. The prevalence of hyperuricemia ranged from 22-66.1%. The highest prevalence 47.0%; (95% CI: 27.9-, 66.2), was seen in Amhara region and the lowest 31.5%; 95% CI: 12.6-50.5), seen in Oromia region: whereas the pooled prevalence hyperuricemia among adults with chronic disease with a random-effects model was 37.5% (95% CI: 30.6). From extracted variables BMI is significantly associated with hyperuricemia.

Conclusion: Despite of hyperuricemia can be easily diagnosed and largely preventable this study showed that hyperuricemia is highly prevalent among adults with chronic diseases, with more than one-third of patients affected. Also, above-normal BMI showed a significantly associated with hyperuricemia. So early identification and targeted prevention strategies needed to reduce the burden of hyperuricemia and complications on these risky groups.

Keywords: Hyperuricemia, Adult, Chronic Disease, Ethiopia, Systematic Review, Meta-Analysis

Citation: Amanuel Aklilu Alemu, Sumeya Hussen Idris, Elias Getahun Bayu, Tsion Kebede Tegene, Gebremedhin Hailay Tsadik, Elias Gashaw Endegnanew, Biruk Tadesse Officer, Haymanot Bekele Urga, Misrak Handamo, Tsion Tesfaye Degefu, Sherefedin Kedir Rashed, Temesgen Teklu Alemayehu, Meron Teklay Girmay, Tewodros Kassahun tarekegn. Prevalence And Predictors of Hyperuricemia Among Adults with Chronic Diseases in Ethiopia: A Systematic Review and Meta-Analysis 2025. J Clin Nephro Uro. 2026. 1(1): 1-7. DOI: doi.org/10.61440/JCNU.2026.v1.01

Introduction

Hyperuricemia, defined as an abnormally elevated serum uric acid concentration, usually greater than 6 mg/dL in women and 7 mg/dL in men [1]. Elevated uric acid has been linked to gout, cardiovascular diseases (CVD), resistant hypertension, insulin resistance, chronic kidney disease (CKD), and progression of type 2 diabetes mellitus (T2DM) [2-5] through mechanisms involving oxidative stress, endothelial dysfunction, and inflammation [6-9].

Current global population wide estimates of hyperuricemia are limited, data from related conditions such as gout indicate a rising trend in both prevalence and disability worldwide [10,11]. Also, similar scenario exists with other chronic health conditions [12].

Hyperuricemia has several side effects that have been linked to different chronic diseases. Endothelial dysfunction, oxidative stress, inflammation, and activation of renin-angiotensin systems, encouraging insulin resistance, promotion of vascular smooth muscle proliferation is associated mechanisms with the diseases [13-16].

In developing countries, report of hyperuricemia prevalence shows around 21 % of adults, with substantial gender differences and increasing trends over time [17].

Despite its recognized clinical importance of hyperuricemia, comprehensive national epidemiological data on hyperuricemia remain limited; several institution-based studies have reported relatively high prevalence within specific adult populations in Ethiopia. Examining these patterns is particularly important given the nation's rising chronic disease prevalence and the potential contribution of hyperuricemia to adverse outcomes. Additionally, limited access to diagnostic and preventive health services in Ethiopia may delay identification and management of hyperuricemia and its associated comorbidities, strengthening their clinical impact [18,19].

Therefore, this study aims to determine the prevalence of hyperuricemia and predictors among adults living with chronic diseases in Ethiopia.

Objectives of the Study

- To determine Prevalence of hyperuricemia among adult with chronic disease in Ethiopia
- To identify predictors of hyperuricemia among adult with chronic disease in Ethiopia

Methods and Materials

Study Design

Systematic review and meta-analysis design was conducted to report the study findings.

Search Strategy

To get eligible studies PubMed, Scopus, PsycInfo, and Google scholar data bases were utilized. The Cochrane acronym POCC (population, Outcome, Condition, and Context) was employed to guide the retrieval of studies across different databases, using appropriate medical subject heading (MeSH) terms and Boolean operators "AND" and "OR". The search terms included

"hyperuricemia" OR "Uric Acid" OR "AND "Prevalence" OR "Risk Factors" OR Predictors AND "Adult" AND "Chronic Disease" OR comorbidity OR" hypertension" OR diabetes OR "Kidney Diseases" AND "Ethiopia". Additionally, manual searching and references of retrieved articles were reviewed to get additional studies. The researchers used the PRESS evidence-based checklist to asses' electronic search strategy [20] and reported the findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020 guidelines [21] (Supplementary file 1).

Eligibility Criteria

- Study period- this study included studies published up to December 2025.
- Study type- this study included all observational studies
- Language -this study included studies published in English languages.
- Population-This study included studies that were conducted among adults with chronic non-communicable disease.
- The study included studies both published and unpublished articles conducted in Ethiopia
- Review articles and studies that did not report the desired outcome will be excluded.

Data Extraction

After finalizing the searching, we conducted data extraction in pairs. The extracted data was recorded in a Microsoft Excel 2013 spreadsheet and included the following information: author's name, publication year, study design, sample size, setting, prevalence of hyperuricemia, and predictors for each specific chronic disease along with their corresponding odds ratios. We focused on extracting variables that were considered factors in more than two studies.

Data Items /Outcome

The primary outcome of this review is to assess the prevalence of hyperuricemia. The secondary outcome is to identify predictors. These factors were determined using the odds ratio (OR), extracted from bivariate analysis of included primary studies.

Study Risk of Bias Assessment /Quality Assessment of Studies
The researchers utilized the modified Newcastle-Ottawa Scale (NOS) for cross-sectional studies to assess the quality of studies. The scale consists of three components: Selection, Comparatively and outcome assessment methods, with a total score of 10 points [22]. Studies that scored five or higher on the NOS were included in the analysis [23]. The quality assessment was independently conducted by the authors, and any discrepancy in the result was resolved through careful examination of the studies by all authors together.

Effect Measures

Proportions were used to measure the effect for the prevalence, while Odds ratio (OR) was used to measure the effect for the risk factors.

Data Analysis and Synthesis Methods

After extracting the eligible studies, the data was exported to Stata software version 14 for analysis. A random-effect model was used due to heterogeneity of studies, which varied across factors such as study setting, patient's characteristics, demographics,

and different risks for the outcome. Heterogeneity among the studies was assessed using Higgin’s I2 to quantify between-study heterogeneity and Cochran’s Q method to identify significance between-study heterogeneity. An I2 test statistics of <50 was declared as low heterogeneity, 50–75% was moderate, and >75% was high heterogeneity [24]. Subgroup analysis was conducted based on region. The funnel plot and Egger’s test were utilized to check for publication bias; while sensitivity analyses were performed to assess robustness of the synthesized results.

Results

Study Selection and Characteristics

The search strategy retrieved a total of 8469 published articles: 4,307 from PubMed, 2451 from Scopus, 1299 from PsycInfo, and 412 from Google Scholar. After removing duplicates using reference management software, 6766 articles remained. Following further screening, 764 articles were assessed for eligibility. Out of these, 754 articles were excluded because they didn’t meet the inclusion criteria. Finally, ten studies were included in the analysis (Figure 1).

The ten studies [25-34] included 2917 participants. All of the included studies were cross-sectional studies and the sample size ranged from 218 to 402 [29,30]. Most studies were conducted in

Amhara region. Among the included studies, the prevalence of hyperuricemia ranged from 22% [32] to 66.1% [30] (Table 1).




Figure 1: PRISMA flow diagram of study selection for Prevalence of hyperuricemia among adult with chronic disease in Ethiopia


Table 1: Characteristics of the Included Studies in the Systematic Review and Meta-Analysis

| Authors Name | Publication Year | Study area | Study design | Sample size | Prevalence with 95 %CI |
|--------------|------------------|-------------|-----------------|-------------|------------------------|
| Rufe NB, | 2025 | Fitche | Cross-sectional | 298 | 41.3(35.7-56.8) |
| Daka OP | 2024 | Gonder | Cross-sectional | 248 | 42.3(36.1-48.4) |
| Addisu B, | 2024 | Mekelle | Cross-sectional | 269 | 43.1(37.1-49.0) |
| Timerga A, | 2021 | Wolkite | Cross-sectional | 270 | 27.4(22.0-32.7) |
| Molla MD, | 2021 | Addis Ababa | Cross-sectional | 402 | 31(26.4-35.5) |
| Yirdaw AK, | 2025 | Gonder | Cross-sectional | 218 | 66.1(59.8-72.3) |
| Woyesa SB, | 2017 | Hawassa | Cross-sectional | 319 | 33.8(28.6-38.9) |
| Arersa KK, | 2020 | Jimma | Cross-sectional | 287 | 22(17.2-26.7) |
| Abrar S, | 2025 | Gurage | Cross-sectional | 222 | 36.9(30.5-43.2) |

**Systematic Review and Meta-Analysis
Prevalence of Hyperuricemia**

A DerSimonian and Laird random-effects model was fitted to determine the pooled effect size.

Accordingly, the pooled prevalence hyperuricemia among adults with chronic disease with a random-effects model was 37.5% (95% CI: 30.6, 44.5) with heterogeneity index (I2) of 94.0% (p <0.001) (Figure 2).




Note: Weights are from random-effects model

Figure 2: Forest plot showing the pooled Prevalence of hyperuricemia among adult with chronic disease in Ethiopia

Heterogeneity and Publication Bias

To adjust and minimize the reported heterogeneity of this study ($I^2=94.0\%$); we performed a subgroup analysis based on the region. The subgroup analysis result is only valid for studies conducted more than once in mentioned region. Accordingly, the highest 47.0% ; (95% CI: 27.9-, 66.2), $I^2 = 97.1\%$) seen in Amhara region and the lowest 31.5% ; 95% CI: 12.6-50.5), $I^2 = 96.2\%$) seen in Oromia region (Figure 3).



Note: Weights and between-subgroup heterogeneity test are from random-effects model

Figure 3: Subgroup analysis of Prevalence of hyperuricemia among adult with chronic disease in Ethiopia

To identify the source reported heterogeneity of this study ($I^2=94.0\%$); meta-regression was conducted using sample size and publication year as a covariate. It was indicated that there is no effect of sample size and publication year on heterogeneity between studies with a P-value of 0.930 & 0.656 respectively.

Furthermore, the presence of publication bias was assessed using Egger’s regression test and visual inspection of a funnel plot. Egger’s test showed statistically significant evidence of publication bias (0.020). Therefore, trim and fill analysis was performed to determine the final effect size. However, a similar effect size was obtained using the model. The visual inspection of the funnel plot suggested an asymmetrical distribution of studies with studies unevenly distributed around the pooled estimate, suggesting potential publication bias or small-study effects. This asymmetry may reflect between-study heterogeneity or selective publication of results rather than true publication bias alone (Figure 4).




Figure 4: Funnel plot to test publication bias in 10 studies with 95% confidence limits

Sensitivity Analysis

Sensitivity analysis was carried out by removing studies step by step to evaluate the effect of a single study on the overall effect estimate. The result indicated removing a single study did not have a significant influence on pooled prevalence (Figure 5).




Figure 5: Sensitivity analysis of pooled Prevalence of hyperuricemia among adult with chronic disease in Ethiopia for each study being removed one at a time

Factor Associated Hyperuricemia Among Adults with Cardiovascular Disease

This meta-analysis examined several sociodemographic and behavioral determinants of hyperuricemia. Seven variables were extracted to identify risk factors associated with hyperuricemia among patients with cardiovascular disease: namely age, gender, place of residence, educational status, physical activity, alcohol consumption and body mass index. Age, gender, residence, education, alcohol consumption, and physical activity showed no statistically significant associations, and most exhibited substantial heterogeneity, suggesting variability across studies. But BMI has an association. Those participants with above-normal BMI had a significantly higher risk of hyperuricemia compared with those with normal BMI (OR = 0.26; 95% CI: 0.18–0.36; $p < 0.001$). There was no heterogeneity among studies ($I^2 = 0.0\%$), indicating consistent evidence (Table 2).

Discussion

Gout and hyperuricemia are increasingly recognized as systemic metabolic conditions that extend beyond joint involvement and are associated with a substantially elevated risk of cardiovascular outcomes, including heart failure, myocardial infarction, and stroke, as well as significant metabolic and renal complications [35]. Globally, these conditions contribute to a growing healthcare burden and are linked to multiple comorbidities and increased mortality, emphasizing the importance of comprehensive clinical recognition and management [36]. Notably, the prevalence of hyperuricemia has been steadily rising in developing countries, largely driven by rapid lifestyle transitions, dietary changes, urbanization, and population aging, further straining already limited health systems [37].

The pooled prevalence of hyperuricemia among adults with chronic diseases (37.5%; 95% CI: 30.6–44.5) is markedly higher than the prevalence reported among type 2 diabetes mellitus patients in Africa (27.28%) and the general population in China (17.4%). this variation might be due to individuals with chronic diseases often present with multiple coexisting risk

factors, which adversely affect uric acid metabolism and renal excretion. In contrast, while type 2 diabetes is a strong metabolic risk factor for hyperuricemia, diabetic populations may still be more heterogeneous in disease duration, treatment status, and

renal involvement, resulting in a comparatively lower pooled prevalence. Also, variation in socio-demographic characteristics and health system capacity for screening may further contribute to variability in prevalence estimates [38,39].

Table 2: Factor Associated Hyperuricemia Among Adults with Cardiovascular Disease

| Determinants | Comparison | No of studies | Sample size | OR (95%CI) | P-value | I2 (%) | Heterogeneity test (p value) |
|---------------------|---------------------------|---------------|-------------|-------------------|---------|--------|------------------------------|
| Age | Below 55 years Vs above | 4 | 1084 | 1.95 (0.89-4.27) | 0.095 | 86.9 | < 0.001 |
| Gender | Female vs male | 3 | 903 | 1.11(0.61 – 2.02) | 0.740 | 77.0 | 0.0013 |
| Residence | Rural vs urban | 3 | 961 | 1.23 (0.94-1.62) | 0.129 | 0.0 | 0.571 |
| Education | Illiterate vs literate | 4 | 1201 | 1.41 (0.840-2.38) | 0.192 | 74.9 | 0.007 |
| Alcohol consumption | Yes vs No | 4 | 1065 | 2.85 (0.59-13.8) | 0.194 | 95.6 | < 0.001 |
| Physical activity | Low Vs moderate and above | 4 | 1201 | 1.65 (0.82-3.31) | 0.158 | 85.2 | < 0.001 |
| BMI | Normal vs above normal | 3 | 816 | 0.26 (0.18-0.36) | < 0.001 | 0.0 | < 0.001 |

The subgroup analysis result revealed, the highest prevalence 47.0%; (95% CI: 27.9-, 66.2) seen in Amhara region and the lowest 31.5%; 95% CI: 12.6-50.5) seen in Oromia region. This difference might be due to differences in population risk profiles, lifestyle patterns, access to diagnostic services, and urbanization level.

Those participants with above-normal BMI had a significantly higher risk of hyperuricemia compared with those with normal BMI (OR = 0.26; 95% CI: 0.18–0.36): different evidence shows that above normal BMI has been shown to causally increase the risk of hyperuricemia via mechanisms involving insulin resistance and adipocytokine pathways that reduce uric acid excretion and promote metabolic dysfunction [40,41].

Conclusion

Given that hyperuricemia can be easily diagnosed through simple laboratory testing and is largely preventable through weight management, dietary modification, and early clinical screening, this study showed that hyperuricemia is highly prevalent among adults with chronic diseases, with more than one-third of patients affected. Also, above-normal BMI showed a significantly associated with hyperuricemia. So early identification and targeted prevention strategies needed to reduce the burden of hyperuricemia and complications on these risky groups.

Limitation of the Study

This systematic review and meta-analysis provided groundbreaking insights on prevalence and predictors of hyperuricemia among patients with chronic disease. However, there are certain limitations to be considered. First due to significant heterogeneity of studies, result should be interpreted with caution. Secondly, we encountered difficulties when comparing our findings due to the absence of systematic reviews and meta-analyses on similar population groups.

Declaration

Ethics Approval and Consent to Participant

Not applicable

Consent for Publication

Not applicable

Availability of Data and Materials

All the data analyzed during the current systematic review and meta-analysis is available with reasonable request from corresponding author

Competing Interests

All the authors declare that they have no competing interests

Funding

Not applicable

Acknowledgment

We would like to thank all authors of studies included in this systematic review and meta-analysis.

References

- George C, Leslie SW, Minter DA. Hyperuricemia. InStatPearls. 2023.
- Du L, Zong Y, Li H, Wang Q, Xie L, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024. 9: 212.
- Kuwabara M, Hisatome I, Ae R, Kosami K, Aoki Y, et al. Hyperuricemia: A new cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases. 2025. 35: 103796.
- Yang H, Ying J, Zu T, Meng XM, Jin J. Insights into renal damage in hyperuricemia: Focus on renal protection. Molecular Medicine Reports. 2025. 31: 1-5.
- Zheng L, Zhu Y, Ma Y, Zhang H, Zhao H, et al. Relationship between hyperuricemia and the risk of cardiovascular events

- and chronic kidney disease in both the general population and hypertensive patients: A systematic review and meta-analysis. *International Journal of Cardiology*. 2024. 399: 131779.
6. Ponticelli C, Podestà MA, Moroni G. Hyperuricemia as a trigger of immune response in hypertension and chronic kidney disease. *Kidney international*. 2020. 98: 1149-59.
 7. Li D, Yuan S, Deng Y, Wang X, Wu S, et al. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. *Frontiers in immunology*. 2023. 14: 1282890.
 8. Wei X, Zhang M, Huang S, Lan X, Zheng J, et al. Hyperuricemia: A key contributor to endothelial dysfunction in cardiovascular diseases. *The FASEB Journal*. 2023. 37: e23012.
 9. Nishizawa H, Maeda N, Shimomura I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. *Hypertension Research*. 2022. 45: 635-40.
 10. Jin S, Wang Y, Yan S, Fu X, Hu X, et al. Global burden and trends of gout incidence and prevalence. *Chinese Medical Journal*. 2025. 138: 3153-62.
 11. Cross M, Ong KL, Culbreth GT, Steinmetz JD, Cousin E, et al. Global, regional, and national burden of gout, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *The Lancet Rheumatology*. 2024. 6: e507-17.
 12. Nishizawa H, Maeda N, Shimomura I. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. *Hypertension Research*. 2022. 45: 635-40.
 13. Shubietah A, Awashra A, Milhem F, Ghannam M, Hattab M, et al. Hyperuricemia and cardiovascular risk: insights and implications. *Critical pathways in cardiology*. 2025: 10-97.
 14. Liu N, Xu H, Sun Q, Yu X, Chen W, et al. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. *Oxidative Medicine and Cellular Longevity*. 2021. 2021: 1470380.
 15. Zhi L, Yuzhang Z, Tianliang H, Hisatome I, Yamamoto T, et al. High uric acid induces insulin resistance in cardiomyocytes in vitro and in vivo. *PloS one*. 2016. 11: e0147737.
 16. Li H, Qian F, Liu H, Zhang Z. Elevated uric acid levels promote vascular smooth muscle cells (VSMC) proliferation via a nod-like receptor protein 3 (NLRP3)-inflammasome-dependent mechanism. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*. 2019. 25: 8457.
 17. Du L, Zong Y, Li H, Wang Q, Xie L, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. *Signal Transduction and Targeted Therapy*. 2024. 9: 212.
 18. Shiferaw F, Letebo M, Misganaw A, Feleke Y, Gelibo T, et al. Non-communicable Diseases in Ethiopia: Disease burden, gaps in health care delivery and strategic directions. *Ethiopian Journal of Health Development*. 2018. 32.
 19. Defar A, Zeleke GT, Berhanu D, Lemango ET, Bekele A, et al. Health system's availability and readiness of health facilities for chronic non-communicable diseases: evidence from the Ethiopian national surveys. *Plos one*. 2024. 19: e0297622.
 20. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, et al. PRESS peer review of electronic search strategies: 2015 guideline statement. *Journal of clinical epidemiology*. 2016. 75: 40-6.
 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*. 2021. 372.
 22. Modesti PA, Reboldi G, Cappuccio FP. Newcastle-Ottawa Quality Assessment Scale (adapted for cross sectional studies). *PLoS One*. 2016.
 23. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC public health*. 2013. 13: 1-7.
 24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ*. 2003. 327: 557.
 25. Rufe NB, Lamesa TA, Mamo AG, Zewude BM, Addisu B, et al. Hyperuricemia and associated factors among adult cardiovascular disease patients at Salale University Comprehensive Specialized Hospital, Fitcha, Central Ethiopia. *PLoS One*. 2025. 20: e0325775.
 26. Daka OP, Jember TB, Tesfa KH. Hyperuricemia and associated factors among hypertensive patients attending an academic hospital of Ethiopia: A cross-sectional study. *Metabolism Open*. 2024. 23: 100312.
 27. Addisu B, Sefew AT, Milkite A, Hika A, Kelem A, et al. Hyperuricemia and Associated Factors in Adult Cardiac Patients in Western Oromia, Ethiopia. *Nutrition and Metabolic Insights*. 2024. 17: 11786388241288668.
 28. Timerga A, Haile K. Evaluation of uric acid disorders and associated factors in essential hypertensive patients at Wolkite University specialized hospital, Southern Ethiopia. *Plos one*. 2021. 16: e0256557.
 29. Molla MD, Bekele A, Melka DS, Teklemariam MD, Challa F, et al. Hyperuricemia and its associated factors among adult staff members of the Ethiopian Public Health Institute, Ethiopia. *International Journal of General Medicine*. 2021. 1437-47.
 30. Yirdaw AK, Ayele YY, Alemu H, Tesfaye T, Hailu W, et al. Prevalence and associated factors of hyperuricemia in chronic kidney disease: evidence from a single-center hospital-based study in Ethiopia, 2024. *Scientific Reports*. 2025. 15: 38938.
 31. Woyesa SB, Hirigo AT, Wube TB. Hyperuricemia and metabolic syndrome in type 2 diabetes mellitus patients at Hawassa university comprehensive specialized hospital, South West Ethiopia. *BMC endocrine disorders*. 2017. 17: 76.
 32. Arersa KK, Wondimnew T, Welde M, Husen TM. Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients attending Jimma Medical Center, Southwestern Ethiopia, 2019. *Diabetes, Metabolic Syndrome and Obesity*. 2020. 2059-67.
 33. Abrar S, Fikadu B, Semaneh A, Getachew A. Prevalence and Determinants of Hyperuricemia Among Type 2 Diabetes Mellitus Patients at Selected Government Hospitals in Gurage Zone: A Cross-Sectional Study. *Journal of Medical Sciences and Health Care Research*. 2025. 2: 1-9.

34. Woldeamlak B, Yirdaw K, Biadgo B. Hyperuricemia and its association with cardiovascular disease risk factors in type two diabetes mellitus patients at the University of Gondar Hospital, Northwest Ethiopia. *Ejifcc*. 2019. 30: 325.
35. Burnier M. Gout and hyperuricaemia: modifiable cardiovascular risk factors?. *Frontiers in cardiovascular medicine*. 2023. 10: 1190069.
36. Timsans J, Palomäki A, Kauppi M. Gout and hyperuricemia: a narrative review of their comorbidities and clinical implications. *Journal of clinical medicine*. 2024. 13: 7616.
37. Al-Worafi YM. Gout and hyperuricemia management in developing countries. In *Handbook of medical and health sciences in developing countries: Education, practice, and research 2024*. 1-42.
38. Alemayehu E, Fiseha T, Bambo GM, Sahile Kebede S, Bisetegn H, et al. Prevalence of hyperuricemia among type 2 diabetes mellitus patients in Africa: a systematic review and meta-analysis. *BMC Endocrine Disorders*. 2023. 23: 153.
39. Huang J, Ma ZF, Zhang Y, Wan Z, Li Y, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. *Global Health Research and Policy*. 2020. 5: 52.
40. Panlu K, Zhou Z, Huang L, Ge L, Wen C, et al. Associations between obesity and hyperuricemia combining mendelian randomization with network pharmacology. *Heliyon*. 2024. 10.
41. Mao T, He Q, Yang J, Jia L, Xu G. Relationship between gout, hyperuricemia, and obesity—does central obesity play a significant role? a study based on the NHANES database. *Diabetology & Metabolic Syndrome*. 2024. 16: 24.